Serum Biomarker Profile in Multiple Sclerosis Treated with Autologous Bone Marrow Transplant
Arina Alexeeva1, Anastasia Chumakova1, Michael Demetriou1, Michael Sy1, Gaby Thai1
1UC Irvine
Objective:
We examined dynamics of serum biomarker profile in patients with multiple sclerosis (MS) following autologous bone marrow transplant (aHSCT).
Background:
Several studies have demonstrated efficacy of autologous bone marrow transplant in treatment of multiple sclerosis. The use of this treatment modality is currently limited pending results of larger a randomized controlled trial and FDA approval. However, as a measure of last resort in select MS patients, this treatment is offered at some institutions. No studies have examined serum biomarker profile dynamics in patients receiving aHSCT.
Design/Methods:
We have collected Octave Biosciences Inc Multiple Sclerosis Disease Activity panel (Octave MSDA) in 13 patients with MS who underwent aHSCT at UCI and maintained disease stability. 6 patients had longitudinal testing during the first year after aHSCT. Clinical, imaging and laboratory data was retrospectively collected. Data was analyzed using R.
Results:
Age-adjusted serum biomarker levels fluctuated from baseline during first year post-treatment. We found that biomarkers of neuroaxonal damage to be elevated shortly after aHSCT and then normalize within 6-12 months. Long-term elevation of B-cell activating factor (BAFF) was observed in all patients likely due to use of B-cell depleting agents either prior to aHSCT or as part of the myeloablative protocol. We also report several correlations between serum biomarker profile and symptomatic status of patients following aHSCT.
Conclusions:
Serum biomarker profile can be considered as an objective and dynamic measure to monitor MS patients after aHSCT.
Disclaimer: Abstracts were not reviewed by Neurology® and do not reflect the views of Neurology® editors or staff.